IL-29 Monoclonal Antibody (247801)

* CHF, excl. 8.1% VAT and shipping costs

Product Description

In sandwich ELISAs, 100% cross-reactivity with recombinant human (rh) IL-28B/IFN-lambda 3 and 20% with rhIL-28A is observed. No cross-reactivity or interference was observed with rhIFN-alpha A, rhIFN-alpha B2, rhIFN-alpha G, rhIFN-alpha I, or rhIFN- beta 1A. Reconstitute at 0.5 mg/mL in sterile PBS. Endoxin level is <0.10 EU per 1 µg of the antibody by the LAL method. IFN-lambdas constitute a novel family of interferons that mediate the induction of anti-viral protection in a wide variety of cells. There are three members in this family, namely lambda1, lambda2, and lambda3, which are also known as IL-29, IL-28A, and IL-28B, respectively. Similar to type I IFNs, IFN-lambdas activate an intracellular signaling to promote gene expression. IFN-lambdas mediate their anti-viral protection through a class II cytokine receptor complex composed of two essential receptor proteins, CRF2-12/IFN-lambdaR1, which is unique to IFN-lambdas, and CFR2-4/IL-10R2, which is shared with IL-10, IL-22, and IL-26 receptors. The IFN-lambdas, IL-28 and IL-29, have recently been reported to prime dendritic cells to induce proliferation of Foxp3-bearing regulatory T cells. DCs that differentiate in response to IFN-lambdas express high levels of class I and II MHC gene products, but low level